

**Ontogeny of Rat CYP2E1 and CYP1A2: A Characterization and a
Pharmacokinetic Model**

A Thesis

Submitted to the College of Graduate Studies and Research

In Partial Fulfillment of the Requirements

for the Degree of Doctor of Philosophy

in the Division of Pharmacy,

College of Pharmacy and Nutrition

University of Saskatchewan

Saskatoon

By

Fawzy Ahmed Elbarbry

PERMISSION TO USE

In presenting this thesis in partial fulfillment of the requirements for a Postgraduate degree from the University of Saskatchewan, I agree that the Libraries of this University may make it freely available for inspection. I further agree that permission for copying of this thesis in any manner, in whole or in part, for scholarly purposes may be granted by the professor or professors who supervised my thesis work or, in their absence, by the Head of the Department or the Dean of the College in which my thesis work was done. It is understood that any copying or publication or use of this thesis or parts thereof for financial gain shall not be allowed without my written permission. It is also understood that due recognition shall be given to me and to the University of Saskatchewan in any scholarly use which may be made of any material in my thesis.

Requests for permission to copy or to make other use of material in this thesis in whole or part should be addressed to:

Head of the Department of Pharmacy
University of Saskatchewan
Saskatoon, Saskatchewan (S7N5C9)

ABSTRACT

Infantile exposure to xenobiotics, e.g. from breastfeeding, poses a serious toxicity risk. Since the toxicokinetic mechanisms that principally determine exposure outcomes undergo a significant developmental maturation, infants may respond to exposures in a different way than adults. Hence, suitable model systems are required to provide risk relevant information in pediatric populations. This dissertation's primary goal was to provide a critical evaluation of two such model systems; first, a pharmacokinetic model that may predict an infant's capacity to eliminate toxicants by cytochrome P-450 (CYP) mechanisms and second, the developing rat as a model of human CYP2E1 and CYP1A2 ontogeny.

The first objective was to evaluate underlying assumptions of a pharmacokinetic model that describes the ontogeny of hepatic CYP activity using the rat. The study recognized some discrepancies with the stated assumptions. The impact of these discrepancies on the potential applicability of the model is discussed. As proof-of-concept, the observed data were fit to a model describing rat CYP2E1 and CYP1A2 ontogeny. A reasonable correlation ($r = 0.75$) was observed between observed and predicted oral clearance values of a CYP2E1 substrate indicating the potential applicability of such a model in risk assessment.

The second objective was to conduct an extensive characterization of rat hepatic CYP2E1 and CYP1A2 ontogeny at mRNA, protein, activity and intrahepatic expression levels. The results were compared to available human data to determine the appropriateness of the rat for assessment of toxicokinetic mechanisms underlying age-dependent differences in susceptibility to toxicity. Similarities in age-dependent changes in mRNA, activity and zonal hepatic expression patterns were noted between the rat and human prior to weaning. Unlike human data, rats show good correlation between changes in CYP2E1 and CYP1A2 activity and transcript levels, but not with the immunoquantifiable protein. Recognizing such similarities and differences between rats and human regarding onset, rate and pattern of CYP ontogeny will

improve the accuracy of rat-to-human extrapolation of developmental toxicokinetic data.

Overall, the dissertation research provides mounting and supportive evidence for the use of such model systems in providing risk-relevant information in pediatric populations and to identify toxicokinetic mechanisms underlying age-dependent differences in susceptibility to toxicity.

ACKNOWLEDGMENTS

Initially I would like to thank my supervisor (Dr. Jane Alcorn) for her excellent guidance and supervision throughout my graduate program. I equally thank the members of my advisory committee, Drs. Krol E., Olkowski A., Janz D., and Zello G. for their helpful instructions and advices. I am grateful to the staff at the animal resource center (ARC) for providing rats and teaching me the various techniques of surgery, canulation, oral dosing and blood collection. I am also indebted to the fellow graduate students at the College of Pharmacy and Nutrition who supported me throughout my PhD program. In particular, I express gratitude to Jennifer, Erica, Erin, Brian and Sam for their support and fruitful scientific, political and social discussions. Thanks to all summer students who gave me the opportunity to teach them, and also learn from them.

I can not forget the significant role that my small family in Canada played in this achievement. My wife (Nehad) and my son (Moaz) were encouraging me all the time and tried their best to create a suitable place for me to think, read and write. I express my gratitude to my parents in Egypt who raised me and fostered me with the skills I need to achieve this success.

I acknowledge the research funding from Natural Sciences and Engineering Research Council (NSERC), Pfizer Canada and University of Saskatchewan. This study would not have been possible without such funding.

PUBLISHED AND SUBMITTED MATERIALS

A modified version of Section 3.2.4 along with Section 4.1.2.2 has been previously published:

Elbarbry F, Wilby K and Alcorn J. Validation of a liquid chromatographic assay of *p*-nitrophenol hydroxylase activity in rat hepatic microsomes: a marker for cytochrome P450 2E1 activity, *J Chromatogr. B.* 2006. 834 (1-2) 199-203.

Modified versions of this dissertation have been presented in abstract forms:

Elbarbry F, Alcorn J. Validating the Assumptions of an Ontogeny Model of Hepatic CYP2E1 and CYP1A2-mediated Drug Clearance. Society of Toxicology in Canada (STC), 38th **Annual Symposium**, Montreal, Quebec. Dec 5-6, 2005.

Elbarbry F, Alcorn J. Validating the Assumptions of an Ontogeny Model of Hepatic CYP2E1 and CYP1A2-mediated Drug Clearance. **The Canadian Society for Pharmaceutical Sciences (CSPS), 8th Annual Symposium**, Toronto, ON. May 29-June 2, 2005.

Elbarbry F, Alcorn J. Validating the Assumptions of an Ontogeny Model of Hepatic Drug Clearance Mechanisms. **7th International ISSX Meeting**, Vancouver, BC. Aug 29-Sept 2, 2004

Elbarbry F, Alcorn J. Maturation of Cytochrome P450 2E1 and Glutathione-S-Transferases. **Association of Faculties of Pharmacy of Canada (AFPC) Conference**, Vancouver, BC. June 10 – 12, 2004.

Elbarbry F, Alcorn J. Maturation of Cytochrome P450 2E1 and Glutathione-S-Transferases. Poster presented at **the 10th Annual Life Science Research Day**, Saskatoon, SK. May 15-16, 2003

A modified version of Sections 3.2.3, 3.2.7, 3.2.8, 3.2.9 has been submitted for publication:

Elbarbry F, McNamara P and Alcorn J. Ontogeny of CYP1A2 and CYP2E1 Expression in Rat Livers. (Submitted to *Toxicol. Sciences*).

A modified version of Section 4.1 is in process for submission:

Alcorn J., **Elbarbry F** and McNamara P. Evaluation of the Assumptions of an Ontogeny Model of Hepatic Cytochrome P450 using CYP2E1 and CYP1A2. (will be submitted to *Drug Metabolism and Disposition*).

TABLE OF CONTENTS

PERMISSION TO USE.....	i
ABSTRACT.....	ii
ACKNOWLEDGMENTS.....	iv
PUBLISHED AND SUBMITTED MATERIALS.....	v
TABLE OF CONTENTS.....	vii
LIST OF TABLES.....	xiv
LIST OF FIGURES.....	xv
LIST OF ABBREVIATIONS, SYMBOLS AND ACRONYMS.....	xviii
1. LITERATURE REVIEW.....	1
I. INTRODUCTION.....	1
II. BACKGROUND.....	3
1. Breastfeeding and Infant Exposure to Chemicals.....	3
1.1 Breastfeeding and its benefits.....	3
1.2 Infant Exposure to Drugs and Chemicals in Breast Milk.....	4
1.3 Assessment of Infant Exposure Risk.....	7
1.3.1 Duration of Exposure (Acute versus Chronic).....	7
1.3.2 Milk to Serum (M/S) Ratio.....	8
1.3.3 Infant Dose as a Percentage of Absolute Maternal Dose.....	9
1.3.4 Infant Steady State Serum Concentration ($C_{SS,Inf}$).....	10
1.3.5 Exposure Index Related to Maternal Concentration ($EI_{(con.)}$).....	13
2. Infant Systemic Clearance as a Determinant of $C_{SS,Inf}$	14
2.1 Hepatic Clearance (Cl_H).....	14
2.1.1 Hepatic Blood Flow.....	15
2.1.2 Plasma Protein Binding.....	16

2.1.3 Hepatic Biotransformation.....	17
2.1.3.1 Ontogeny of Hepatic CYP Enzymes.....	19
2.1.3.1.1 Human CYP Enzymes	19
2.1.3.1.2 Rat CYP Enzymes.....	21
2.1.3.1.3 CYP2E1 Enzyme	23
2.1.3.1.4 CYP1A2 Enzyme.....	25
2.1.3.2 Ontogeny of Phase II Enzymes.....	28
2.1.3.2.1 Glucuronide Conjugation.....	28
2.1.3.2.2 Sulfate Conjugation	29
2.1.3.2.3 N-acetylation.....	29
2.1.3.2.4 Glutathione-S-Transferases (GST)	30
3. Relevance of CYP Ontogeny to Developmental Toxicity.....	32
4. Methods Used to Study the Ontogeny of Hepatic Drug Metabolizing Enzymes	33
4.1 <i>In Vivo</i> Approach	34
4.2 <i>In Vitro</i> Approach	34
4.2.1 mRNA Expression Level	35
4.2.2 Protein Expression Level	35
4.2.3 Catalytic Enzyme Activity	36
5. Developmental Changes in Zonal Expression of CYP Enzymes	37
6. Approaches to Predict Hepatic Clearance.....	37
6.1 Prediction from <i>In Vitro</i> Data	37
6.2 Allometric Scaling	38
6.3 Physiologically-Based Pharmacokinetic (PBPK) Models	40
7. Development of a Pharmacokinetic Model of Hepatic CYP-Mediated Elimination...	41

8. Use of Rats as an Animal Model in Studying CYP Ontogeny	42
9. Relevance of the Project to Paediatric Health and Developmental Toxicology	44
2. PURPOSE OF THE PROJECT	46
3. MATERIALS AND METHODS	49
3.1 Materials	49
3.1.1 Animals	49
3.1.2 Chemicals and Reagents	50
3.2 Methods.....	50
3.2.1 Preparation of Hepatic Microsomes and Cytosols.....	50
3.2.2 Determination of Microsomal and Cytosolic Protein Content	51
3.2.3 Microsomal Incubation with CYP2E1 and CYP1A2 Probe Substrates.....	51
3.2.3.1 CZX hydroxylation activity	53
3.2.3.2 PNP hydroxylation activity.....	53
3.2.3.3 Methoxyresorufin-O-dealkylase (MROD) activity.....	53
3.2.3.4 Phenacetin-O-dealkylase (POD) activity	54
3.2.4 HPLC Analyses.....	54
3.2.4.1 CZX hydroxylation activity	55
3.2.4.2 PNP hydroxylation activity	56
3.2.4.3 Methoxyresorufin-O-dealkylase (MROD) activity.....	57
3.2.4.4 Phenacetin-O-dealkylase (POD) activity	57
3.2.5 Measurement of General Glutathione-S-Transferases (GST) Activity.....	58
3.2.6 Age-Dependent Scaling Factors and Model Development.....	59
3.2.7 Protein Expression Analyses.....	60
3.2.8 mRNA Expression Analyses.....	61
3.2.8.1 RNA isolation	61
3.2.8.2 Primer design	61

3.2.8.3 Real-Time RT-PCR.....	62
3.2.9 Immunohistochemical Analyses	63
3.2.10 Oral Clearance Study with Chlorzoxazone.....	64
3.2.10.1 Animals	64
3.2.10.2 Study design.....	65
3.2.10.3 HPLC assay of CZX	66
3.2.11 Kinetic and Statistical Analyses.....	67
4. RESULTS	68
4.1 Validation of the Assumptions of a CYP Model of Ontogeny	68
4.1.1 Age-Dependent Changes in Hepatic Scaling Factors (HSF)	68
4.1.1.1 Total Body and Liver Weights	68
4.1.1.2 Hepatic Microsomal Protein Content.....	69
4.1.1.3 Hepatic Scaling Factor (HSF).....	70
4.1.1.4 Age-Dependent Changes in Total CYP Protein Content.....	71
4.1.2 Enzyme Kinetic Studies in Rat Hepatic Microsomes	72
4.1.2.1 Assessment of the Optimum Incubation Conditions.....	72
4.1.2.2 Validation of the HPLC Methods	73
4.1.2.3 Developmental Changes in K_M Value	75
4.1.2.4 Developmental Changes in V_{max} Value	77
4.1.2.5 Developmental Changes in V_{max} Value Using a Second Probe Substrate	78
4.1.2.6 Correlation between Age-Dependent Changes in Catalytic CYP Activity and Immunoreactive Protein Levels	82
4.1.2.7 Eadie-Hofstee Plots.....	84
4.2 Development of an Ontogeny Model of CYP2E1 and CYP1A2 Enzymes in Rats.	85
4.2.1 Developmental Maturation of CYP Activity	85

4.2.1.1 Age-Specific Infant Scaling Factors	85
4.2.1.2 Model Development.....	87
4.2.1.3 Model Selection	87
4.2.2 Age-Dependent Changes in Chlorzoxazone Oral Clearance in Rats.....	90
4.3. Characterization of the Ontogeny of CYP2E1 and CYP1A2 in Rats	94
4.3.1 Ontogeny of Rat Hepatic CYP2E1 and CYP1A2 mRNA	94
4.3.1.1 Optimization of Real-Time RT-PCR Conditions	94
4.3.1.2 Age-Dependent Changes in mRNA Expression of Rat Hepatic CYP2E1 and CYP1A2	94
4.3.2 Ontogeny of Rat Hepatic CYP2E1 and CYP1A2 Protein Expression	95
4.3.3 Ontogeny of Rat Hepatic CYP2E1 and CYP1A2 Activity.....	97
4.3.4 Correlation between Different Ontogeny Patterns of CYP2E1 and CYP1A2 Enzymes in Rats.....	98
4.3.4.1 CYP Immunoreactive Protein and its mRNA Level.....	98
4.3.4.2 CYP Immunoreactive Protein and its Catalytic activity	98
4.3.4.3 CYP mRNA and its Catalytic Activity	98
4.3.5 Ontogeny of Zonal Expression of Rat Hepatic CYP2E1 and CYP1A2 Activity	101
4.3.6 Ontogeny of Rat Hepatic Glutathione-S-Transferases (GST) Activity	104
4.3.6.1 Age-Dependent Changes in Cytosolic Protein Content	105
4.3.6.2 Age-Dependent Changes in Total Cytosolic GST Activity	105
5. DISCUSSION	106

5.1 Evaluation of the Assumptions of an Ontogeny Model of CYP Enzyme Activity Model	106
5.1.1 Development and Relevance of the Model	106
5.1.2 Developmental Changes in Hepatic Scaling Factors (HSF)	108
5.1.2.1 Developmental Changes in Microsomal Protein (MP) Content in Rat Livers	108
5.1.2.2 Developmental Changes in Rat Liver Weight (LW) and Body Weight (BW)	109
5.1.2.3 Consequences on the Model	110
5.1.3 Developmental Changes in Metabolic Intrinsic Clearance (Cl_{int})	110
5.1.3.1 Developmental Changes in Substrate Affinity (K_M)	111
5.1.3.1.1 Inefficient probe substrate specificity	112
5.1.3.1.2 Non-specific protein binding in hepatic microsomes	113
5.1.3.1.3 Microsomal Membrane Composition	115
5.1.3.2 Developmental Changes in Functional Enzyme Activity (V_{max}) and Correlation to Functional CYP Protein	115
5.1.3.3 Consequences on the Model	118
5.1.4 Correlation between CYP Enzyme Activity Levels Determined Using Two Probe Substrates.....	119
5.1.5 Conclusion	119
5.2 Development of a Pharmacokinetic Model of Rat CYP2E1 and CYP1A2 ...	120
5.3 Characterization of Rat CYP2E1 and CYP1A2 Ontogeny	125
5.3.1 Ontogeny of mRNA Expression	127
5.3.1.1 CYP2E1	127
5.3.1.2 CYP1A2.....	128
5.3.2 Ontogeny of immunochemical CYP Protein Expression.....	129

5.3.2.1 CYP2E1	129
5.3.2.2 CYP1A2	130
5.3.3 Ontogeny of Catalytic CYP Enzyme Activity	131
5.3.3.1 CYP2E1	132
5.3.3.2 CYP1A2	132
5.3.4 Correlation between the CYP Ontogeny Profiles in Rats	133
5.3.5 Ontogeny of Zonal Expression of CYP2E1 and CYP1A2	133
5.3.6 Toxicological Relevance of Characterization of CYP Ontogeny	135
5.4 Characterization of the Ontogeny of Cytosolic GST Enzymes	137
5.5 Conclusion and General Remarks	138
6. REFERENCES	142
APPENDIX I	169

LIST OF TABLES

Table 1.1 Example of maternally-administered medications that may have possible effects on the nursing infant.	5
Table 1.2 Examples of substrates metabolized/bioactivated by CYP2E1	24
Table 1.3 Examples of substrates metabolized/bioactivated by CYP1A2	27
Table 1.4 Human GST isozymes.....	31
Table 3.1 Selected enzymatic reactions mediated by CYP2E1 and CYP1A2	52
Table 3.2 Primer sequences and amplicon sizes for real-time RT-PCR analysis	62
Table 3.3 General real-time RT-PCR protocol	62
Table 3.4 Sizes of feeding and blood sampling needles used in CZX <i>in vivo</i> oral clearance study	65
Table 4.1 Age-dependent Changes in mean (\pm SD) body and liver weights for male Sprague-Dawley rats	68
Table 4.2 Results of preliminary experiments in male rat hepatic microsomes to assess optimum incubation conditions.....	73
Table 4.3 Method validation parameters for the HPLC assays.....	73
Table 4.4 Age-specific infant scaling factor estimates for CYP2E1 and CYP1A2	80
Table 4.5 Parameter estimates for the predictive models of CYP2E1 and CYP1A2-mediated hepatic clearance in rats	88
Table 4.6 Pharmacokinetic parameter estimates following a 30 mg/kg oral dose of CZX to male Sprague-Dawley rats at different developmental ages.....	92
Table 4.7 Optimal annealing temperatures and standard curve ranges for <i>CYP2E1</i> , <i>CYP1A2</i> and β - <i>actin</i> genes for real-time RT-PCR analysis	94

LIST OF FIGURES

Figure 1.1 Interrelationship between factors affecting infant exposure to drugs in breast milk and the resulting pharmacological/toxicological response	12
Figure 1.2 Average level of cytochrome P450 (CYP) enzyme content of adult human liver microsomes and the estimation of the contribution of individual CYP enzymes in the metabolism of drugs currently available on the market.....	20
Figure 1.3 Strategy for extrapolation of <i>in vitro</i> intrinsic clearance to <i>in vivo</i> hepatic metabolic clearance.....	21
Figure 3.1 Glutathione-S-Transferases (GST)-mediated conjugation of 1-chloro-2,4-dinitrochlorobenzene (CDNB) with glutathione (GSH)	59
Figure 4.1 Wet liver weight (g) normalized to total body weight (g) in male Sprague-Dawley rats	69
Figure 4.2 Mean (\pm SD) hepatic microsomal protein content in male Sprague-Dawley rats.....	70
Figure 4.3 Mean (\pm SD) hepatic scaling factor (mg/g body weight) in male Sprague-Dawley rats	71
Figure 4.4 Mean (\pm SD) total hepatic microsomal CYP protein content (nmol/mg microsomal protein) in male Sprague-Dawley rats.....	72
Figure 4.5 Representative HPLC chromatograms of rat hepatic microsomes after incubation with A) chlorzoxazone, B) ρ -nitrophenol	74
Figure 4.6 Representative HPLC chromatograms of rat hepatic microsomes after incubation with A) methoxyresorufin and B) phenacetin.....	75
Figure 4.7 Michaelis-Menten constant (K_M) estimates for CYP2E1-mediated chlorzoxazone hydroxylase activity (A) and CYP1A2-mediated methoxyresorufin-O-dealkylation (MROD) activity (B).....	76
Figure 4.8 V_{max} estimates for CYP2E1-mediated chlorzoxazone hydroxylase activity (A) and CYP1A2-mediated methoxyresorufin-O-dealkylase activity (B) as a function of developmental age in male Sprague-Dawley rat.....	78
Figure 4.9 V_{max} estimates for CYP2E1-mediated PNP hydroxylase activity (A) and CYP1A2-mediated POD activity (B) as a function of developmental age in male Sprague-Dawley rat.....	79

Figure 4.10 Correlation between infant scaling factor estimates for (A) ρ -nitrophenol as a function of chlorzoxazone ($r = 0.80$); (B) Phenacetin as a function of methoxyresorufin ($r = 0.89$).....	81
Figure 4.11 Age-dependent changes in enzyme activity (open circle) as a function of its immunoreactive CYP protein levels (closed circle) in rat hepatic microsomes	83
Figure 4.12 Eadie-Hofstee plots of CZX hydroxylation catalyzed by rat hepatic microsomes from different ages.....	84
Figure 4.13 Eadie-Hofstee plots of MROD activity catalyzed by rat hepatic microsomes from different ages	84
Figure 4.14 Infant scaling factors (ISF) as a function of age for CYP2E1 and CYP1A2.	86
Figure 4.15 Plot output of calculated and observed ISF data versus age using the model given in equation 4.1 for CYP2E1 (A) and CYP1A2 (B).....	89
Figure 4.16 Mean \pm SD serum concentration versus time curves of chlorzoxazone after 30 mg/kg oral dose in male Sprague Dawley rats ($n = 4$) at different developmental ages.....	91
Figure 4.17 Age-related correspondence between calculated and observed CZX oral clearance (Cl/F) values (A) and plot output of calculated versus observed CZX Cl/F data using CYP2E1 ontogeny model.	93
Figure 4.18 Age-related variations in rat hepatic CYP2E1 and CYP1A2 mRNA expression levels.	95
Figure 4.19 Immunoblots of age-dependent rat hepatic microsomes and rat CYP2E1 purified protein.....	96
Figure 4.20 Immunoblots of age-dependent rat hepatic microsomes and rat CYP1A2 purified protein.....	97
Figure 4.21 Age-related changes in rat hepatic CYP2E1 and CYP1A2 protein expression.	97
Figure 4.22 Developmental changes in expression of (A) CYP2E1 and (B) CYP1A2 mRNA, protein and activity levels in rat livers	99

Figure 4.23 Age-dependent changes in CYP enzyme activity (open circle) as a function of mRNA levels (closed circle) in rat hepatic microsomes. 100

Figure 4.24 Immunohistochemical localization of CYP2E1 in representative rat livers....
..... 102

Figure 4.25 Immunohistochemical localization of CYP1A2 in representative rat livers....
..... 103

Figure 4.26 Mean (\pm SD) hepatic cytosolic protein content in male Sprague-Dawley rats.
..... 104

Figure 4.27 Age-related changes in hepatic cytosolic GST activity in rats. 105

Figure 5.1 Calculation of a human equivalent exposure dose from laboratory animal toxicity data..... 124

LIST OF ABBREVIATIONS, SYMBOLS AND ACRONYMS

\pm	plus or minus
$^{\circ}\text{C}$	degree Celsius
AAG	alpha ₁ -acid glycoprotein
ADME	Absorption, distribution, metabolism and elimination
AhR	aryl hydrocarbon receptor
AIC	akaike information criterion
AUC _∞	area under the serum concentration-time curve
ARNT	aryl hydrocarbon receptor nuclear translocator
BW	body weight
BrW	brain weight
CAR	constitutive androstane receptor
CDNB	1-chloro-2,4 dinitrochlorobenzene
CI	confidence interval
Cl/F	oral clearance
Cl _H	hepatic clearance
Cl _{int}	intrinsic clearance
Cl _{S,Inf}	infant systemic clearance
Cl _{S,Mat}	maternal systemic clearance
C _{max}	maximum serum concentration
C _{SS,Inf}	infant steady state serum concentration
C _{SS,Mat}	maternal steady state serum concentration
CYP	cytochrome P450
CZX	chlorzoxazone
DAB	3,3' diaminobenzidine hydrochloride
DME	drug metabolizing enzymes
Dose _{Inf}	drug dose given to the infant
EDTA	ethylenediamine tetra acetate
EI _(Conc)	exposure index related to maternal serum concentration
EI _(Dose)	exposure index related to maternal dose
E _H	hepatic extraction ratio
EPA	US environment protection agency
ER	endoplasmic reticulum
EROD	ethoxyresorufin dealkylase
F	bioavailability
FDA	US Food and Drug Administration
FFA	free fatty acids
4-NC	p-nitrocatechol
f _u	fraction of the drug unbound in plasma
GH	growth hormone
GIT	gastrointestinal tract
GSH	glutathione

GST	glutathione-S-transferases
HAAs	heterocyclic aromatic amine
HC	Health Canada
HNF	hepatocyte nuclear factor
HPLC	High Pressure Liquid Chromatography
HSF	hepatic scaling factor
IHC	immunohistochemistry
ISF	infant scaling factor
ISF _D	a fitted parameter for the model equation
IV	intravenous
k	first-order rate constant
K _M	Michaelis-Menten constant
λ _z	terminal elimination rate constant
LOD	limit of detection
LOQ	limit of quantitation
LW	liver weight
MC	3-methylcholanthrene
MeIQx	2-amino-3,8-dimethylimidazole[4.5]quinoxaline
mg	milligram(s)
min	minute(s)
μL	microliter(s)
mL	milliliter(s)
μm	micrometer(s)
mm	millimeter(s)
mM	millimole(s) per liter
MLP	maximum lifespan potential
MP	microsomal protein
MR	methoxyresorufin
MROD	methoxyresorufin-O-dealkylase
(M/S)	milk to serum ratio
NADPH	nicotinamide adenine dinucleotide phosphate (reduced)
NAPQI	N-acetyl-p-benzoquinoneimine
NAT	N-acetyl transferases
NF	nuclear factor
nM	nanomole(s) per liter
NSAIDs	non-steroidal anti-inflammatory drugs
OSF	ontogeny scaling factor
PAGE	polyacrylamide gel electrophoresis
PAHs	polycyclic aromatic hydrocarbons
PAPS	3'-phosphoadenosine-5'-sulphophosphate
PBPK	physiologically-based pharmacokinetic
PBS	phosphate buffered saline
PBSt	phosphate buffered saline with 0.05 % tween 20
PD	postnatal day
pH	negative logarithm of hydrogen ions to the base 10
PK	pharmacokinetics

PNP	ρ -nitrophenol
POD	phenacetin-O-dealkylase
PP	periportal
psi	pounds per square inch
PV	perivenous
PVDF	polyvinylidene difluoride
PXR	pregnane-X-receptor
QC	quality control
Q_H	hepatic blood flow
r^2	coefficient of determination
RHSF	relative hepatic scaling factor
RSD	relative standard deviation
RT-PCR	reverse transcription polymerase chain reaction
SD	standard deviation
SDS	sodium dodecyl sulfate
SULT	sulfotransferases
τ	infant nursing interval
$t_{1/2}$	Elimination half life
TCDD	2,3,7,8 tetrachlorodibenzo-p-dioxin
t_{max}	time to reach maximum serum concentration
UDP	uridine 5'diphosphate
UGTs	uridine 5'diphosphate glucuronosyl-transferases
UMB	umbelliferone
UV	ultraviolet
V_d	volume of distribution
$V_{d,ss}$	apparent volume of distribution at steady-state
V_{max}	maximal enzyme activity
V_{Milk}	volume of milk ingested by infant

1. LITERATURE REVIEW

I. INTRODUCTION

Epidemiological research provides convincing evidence that breastfeeding is advantageous to the breast-fed infant, lactating mother and society. However, the ability of most drugs and chemicals to transfer from maternal plasma to breast milk puts the suckling infant under an uncertain exposure risk to harmful xenobiotics and raises concerns about breastfeeding safety. When a nursing mother is exposed to a xenobiotic(s), either from the environment or through drug therapy, a decision to discontinue the exposure (e.g. stop medication) or discontinue breast feeding is largely based on data regarding the ability of the drug to appear in breast milk, the amount transferred to the suckling infant and, more importantly, the ability of the suckling infant to handle such an exposure. Despite the growing information about the ability of chemicals to transfer into breast milk and the numerous methods developed to estimate the amount exposed to the suckling infant, very little is known regarding the ability of the infant to deal with the exposed dose. Following an external exposure dose, pharmacokinetic processes determine the concentration of a xenobiotic in the biophase. In many instances it is the capacity of the detoxification mechanisms to eliminate a xenobiotic that poses as the major underlying cause for a toxic outcome following an exposure.

Detoxification systems undergo significant maturation during postnatal development. In human paediatric populations, such age-related differences in elimination mechanisms are generally poorly understood. However, for a given dose, the rate and pattern of the ontogeny of elimination processes will alter the toxicological significance of a xenobiotic in an age-dependent manner and such developmental maturation will confound the extrapolation of toxicity data obtained in adults to the

developing infant. Although the recent establishment of the Children's PK Database (available at <http://www2.clarku.edu/faculty/dhattis>), a database presently under construction to identify differences in pharmacokinetics during development, facilitates extrapolation of risks between adults and infants, this database still falls short of providing sufficient information for the adequate extrapolation of toxicity data, particularly for environmental toxicants.

Interspecies extrapolation of toxicity studies performed with the developing animal is one potential approach proposed to elucidate the impact of the maturation of toxicokinetic processes on age-dependent differences in susceptibility to toxicity and to allow inclusion of risk-relevant information on the developing animal into risk assessment models. An animal model that can, at the very least, identify an underlying toxicokinetic mechanism for age-dependent differences in susceptibility to toxicity has great value in risk assessment. However, because of the interrelationship between genetic and environmental factors that influence the pattern and rate of xenobiotic elimination, a perfect animal model is unlikely to be found. Relevant differences will always exist between human and animal models and these differences will pose serious challenges for qualitative and quantitative predictions of human toxicological outcomes. Translating animal data to humans requires an understanding of how and where these systems are similar and different to evaluate their impact on extrapolation to human exposure risks.

This dissertation takes a systems level approach (i.e. evaluation of mRNA, protein and function) in the evaluation of two detoxification mechanisms, Cytochrome P450 (CYP) 2E1 and CYP1A2. This evaluation will provide critical descriptive information necessary to known information on human CYP ontogeny and to draw comparisons that determine the appropriateness of the developmental animal model system for assessment of toxicokinetic mechanisms underlying age-dependent differences in susceptibility to toxicity. Furthermore, this dissertation evaluates critical assumptions of a pharmacokinetic model that describes the ontogeny of CYP enzymes for its application as a risk assessment tool when infants are exposed to xenobiotics present in breast milk. Literature to date indicates that CYP enzymes in humans are regulated in a similar manner to rodents¹. Therefore rodents are frequently used to provide initial information

about xenobiotic elimination in humans. Accordingly, a rat model system was used to evaluate the underlying assumptions of a pharmacokinetic ontogeny model of CYP enzyme-mediated clearance. Furthermore, rat and human CYP2E1 and CYP1A2 enzymes exhibit high homology and similar substrate profiles²⁻⁴. This could allow use of the rat as an appropriate model to study the developmental expression and function of human CYP2E1 and CYP1A2.

For the purpose of this literature review, the term infant encompasses ages from birth to 2 years and children from 2 years to 12 years of age in humans. However, the term neonate includes birth to postnatal day 21, weanling indicates postnatal days 21 to 28/35 and juvenile encompasses age from postnatal days 28/35 to 49/70 days for rat.

II. BACKGROUND

1. Breastfeeding and Infant Exposure to Chemicals

1.1 Breastfeeding and its Benefits

Extensive epidemiological research has identified diverse and compelling advantages of breastfeeding for infants, mothers, families, and societies and the use of human milk for infant feeding⁵. These advantages include health, social, environmental, and economic benefits⁵. Thus, current guidelines set out by international (i.e. World Health Organization and United Nations Children's Fund) and national (i.e. Canadian Pediatric Society, Health Canada and Dietitians of Canada) organizations recommended that infants be exclusively breastfed for at least the first six months of life, and continue breastfeeding with complementary foods for up to two years of age and beyond⁶⁻⁸. Surveys in Canada and United States report that approximately 70% of women initiate breastfeeding and 30% continue to breastfeed their infants to 6 months of age⁵.

The unique components of human milk make it superior for infant feeding, and differs markedly from all substitute feeding preparations⁹. The nutrients, enzymes, growth factors, hormones and immunological and anti-inflammatory properties of

human milk contribute to reductions in the incidence and severity of acute infectious diseases such as sepsis/meningitis¹⁰, otitis media¹¹, respiratory tract infections¹², gastroenteritis¹¹ and necrotizing enterocolitis¹³. As well, studies correlate breastfeeding with reduced incidences of sudden infant death syndrome^{14,15}, Crohn's disease, insulin-dependent diabetes, lymphoma and allergic diseases^{13,15,16} and reduced prevalence of childhood obesity^{17,18}. Furthermore, breastfeeding may enhance performance on tests of cognitive developments and achievement of better academic scores^{19,20}. Such health benefits may increase with duration and exclusivity of breastfeeding²¹.

Breastfeeding and lactation have many important benefits for nursing women. These benefits include decreased postpartum bleeding and more rapid uterine involution²², reduced risk of epithelial ovarian cancer²³ and breast cancer^{24,25}, reduced risk of hip fracture in old age^{26,27} and faster return to the pre-pregnancy weight²⁸. The act of breastfeeding delays resumption of ovulation and increases child spacing²⁹. Finally, breastfeeding is associated with increased maternal-infant bonding and maternal sense of worth⁵.

Breastfeeding has important social, economic and environmental benefits. These benefits include reduced health care costs due to reduced risk of infant illness and duration of hospitalization^{11,13}. Also breastfeeding is associated with increased family saving due to the greater cost of formula feeding compared to breastfeeding cost¹¹ in addition to lower parental absence from work, and reduced environmental load for disposing formula cans and bottles⁵. Some countries, including Canada, have recognized the potential economical savings from breastfeeding and provide a subsidy to low income mothers for each month of breastfeeding¹¹.

1.2 Infant Exposure to Drugs and Chemicals in Breast Milk

Almost all maternally administered drugs and environmental chemicals appear in breast milk and find their way into the breast-fed infant³⁰⁻³³. Consequently, breast milk constitutes a major exposure route to chemicals for nursing infants. Governmental and regulatory agencies have become gravely concerned about the presence of chemicals in breast milk, particularly in light of recent surveys that suggest approximately 90% of

women take at least one medication, more than 20% take at least two or more medications in the first week after delivery and more than 5% of nursing mothers receive long-term drug therapy^{30,34} (Table 1.1).

Table 1.1- Example of maternally-administered medications that may have possible effects on the nursing infant. Adapted from references (37-39)

Drug	Reported or possible Effects on the Nursing Infant
1. Cytotoxic Drugs	
Cyclosporine	Possible immune suppression, carcinogenesis
Doxorubicin	Possible immune suppression, carcinogenesis
Methotrexate	Possible immune suppression, carcinogenesis
2. Drugs of Abuse	
Amphetamine	Irritability, poor sleeping pattern
Cocaine	Intoxication, irritability, seizures, diarrhea
Heroin	Tremors, restlessness, poor feeding
3. Cardiovascular Drugs	
Acebutolol	Hypotension, bradycardia, tachypnea
Atenolol	Cyanosis, bradycardia
Amiodarone	Possible hypothyroidism
4. Antipsychotics	
Chlorpromazine	Drowsiness, decline in developmental scores, lethargy
Haloperidol	decline in developmental scores
5. Antibiotics	
Amoxicillin	None
Nalidixic acid	Hemolysis in infants with glucose-6-phosphate-dehydrogenase (G-6-PD) deficiency.
Nitrofurantoin	Hemolysis in infants with (G-6-PD) deficiency.
Tetracycline	Negligible absorption by infant
6. Others	
Phenobarbital	Sedation, infantile spasms
Sulfasalazine	Bloody diarrhea
Caffeine	Irritability, poor sleeping pattern, slower elimination